长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000661 长春高新

已收盘 01-12 15:00:00

{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":103.57,"timestamp":1768201422000,"preClose":97.9,"halted":0,"volume":16942649,"delay":0,"changeRate":0.0579,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":5.67,"latestTime":"01-12 15:00:00","open":98,"high":106.65,"low":97.5,"amount":1725000000,"amplitude":0.0935,"askPrice":103.58,"askSize":13,"bidPrice":103.57,"bidSize":227,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":97.9,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":107.69,"lowLimit":88.11,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.74,"roa":"--","peRate":44.053594,"roe":"5.03%","epsLYR":6.42,"committee":0.815739,"marketValue":42250000000,"turnoverRate":0.0424,"status":0,"floatMarketCap":41388000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2602948185","title":"1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602948185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602948185?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:41","pubTimestamp":1768203693,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日长春高新涨5.79%，收盘报103.57元，换手率4.24%，成交量16.94万手，成交额17.25亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共83家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4219，较上一交易日上涨1.54%，近一年上涨18.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","161726","399441","BK0188","BK0028","BK0075","BK0057","BK0046"],"gpt_icon":0},{"id":"2602329517","title":"长春高新：拥有逾40种临床阶段候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2602329517","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602329517?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:15","pubTimestamp":1767950111,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，截至公司招股说明书最后实际可行日期，我们拥有逾40种处于临床阶段或已提交新药临床试验申请的候选药物，其中包括14种处于III期临床或新药上市申请阶段的候选药物及15种1类创新药，具体情况可参见公司港股招股书相关内容；截止2025年底的准确可披露信息情况请关注公司后续年度报告中相关内容，同时最近一个季度内公司重点创新产品的相关临床进展可参见前期已披露的相关公告，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900027612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","000661","BK0188","BK0046","BK0057","BK0239"],"gpt_icon":0},{"id":"2602326167","title":"长春高新：下属公司PEG原料用于长效生长激素","url":"https://stock-news.laohu8.com/highlight/detail?id=2602326167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602326167?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:03","pubTimestamp":1767949390,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)01月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司旗下金派格医用级peg是否可以运用在脑机工程上长春高新回复：感谢您对公司的关注，公司下属公司所生产的PEG相关原料目前主要应用于公司长效生长激素产品中，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900027075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0057","000661","BK0075","BK0046","BK0028","BK0239"],"gpt_icon":0},{"id":"2601352794","title":"长春高新最新公告：子公司注射用GenSci136境内生产药品注册临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601352794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601352794?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:27","pubTimestamp":1767864454,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司控股子公司金赛药业注射用GenSci136的境内生产药品注册临床试验申请获国家药品监督管理局受理。该药物拟用于治疗免疫球蛋白A肾病（IgAN），属于治疗用生物制品1类药物。IgAN是最常见的原发性肾小球疾病，现有治疗方法存在未满足的临床需求。如临床试验进展顺利，将有助于公司丰富产品线，提升竞争力，但存在不确定性，敬请投资者注意风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800027578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0075","000661","BK0057","BK0028","BK0239"],"gpt_icon":0},{"id":"2601100351","title":"长春高新(000661.SZ)子公司褪黑素颗粒上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601100351","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601100351?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:34","pubTimestamp":1767861242,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司——长春金赛药业有限责任公司(“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业褪黑素颗粒的境内生产药品注册上市许可申请获得受理。公告显示，褪黑素颗粒是金赛药业研发的一款儿童神经精神领域产品,属于化学药品4类，能够通过激活视交叉上核的MT1及MT2受体来调节视交叉上核的神经活动，显示出诱导睡眠的作用。拟用于改善儿童期伴随神经性发育障碍的入睡困难。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0057","000661","BK0075","BK0046","BK0028","BK0239"],"gpt_icon":0},{"id":"2595711412","title":"股市必读：长春高新（000661）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595711412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595711412?lang=zh_cn&edition=full","pubTime":"2025-12-31 02:27","pubTimestamp":1767119231,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，长春高新报收于92.74元，下跌0.53%，换手率0.88%，成交量3.5万手，成交额3.26亿元。董秘最新回复投资者： 董秘先生：公司股价跌成这样，H股还发吗？当日关注点来自交易信息汇总：12月30日主力资金净流出1149.88万元，散户资金净流入1671.67万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100001992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0028","BK0057","BK0239","BK0075","BK0188"],"gpt_icon":0},{"id":"2595794095","title":"长春高新：目前H股相关申请材料已于前期递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2595794095","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595794095?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:12","pubTimestamp":1767096720,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月30日，长春高新在互动平台回答投资者提问时表示，目前H股相关申请材料已于前期递交，公司会结合监管要求、市场行情、实际经营情况等综合考虑H股相关工作推进情况。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251230/c673641129.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251230/c673641129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0188","BK0239","BK0046","000661","BK0028","BK0075","BK0057"],"gpt_icon":0},{"id":"2595671707","title":"长春高新：推进重点新产品销售推广工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2595671707","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595671707?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:09","pubTimestamp":1767082152,"startTime":"0","endTime":"0","summary":"对于新产品来说，鉴于相关新产品为最近一两年内刚刚开始销售，基于医药产品尤其是新药品的行业特点，短期内需要一定的市场培育期，因此会出现费用投入与收入贡献不匹配的情况，后续公司会积极推进痛风相关的金蓓欣、癌性厌食相关的美适亚等重点新产品的销售推广工作，推动相关新产品能够为公司带来新的业绩增长点，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000022610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0028","BK0046","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2594260943","title":"长春高新：销售费用增长因新产品推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2594260943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594260943?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:30","pubTimestamp":1766741433,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年上半年销售费用同比增长超30%，但净利润同比下滑25%，请说明销售费用的主要开支项及与营收增长不匹配的原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0057","BK0046","000661","BK0188","BK0075"],"gpt_icon":0},{"id":"2594267006","title":"长春高新：优先推动产品在国内销售推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2594267006","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594267006?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:12","pubTimestamp":1766740342,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月26日在投资者关系平台上答复投资者关心的问题。为什么贵公司不再美国FDA申请做金蓓欣临床试验？因此，目前公司基于相关产品在国内市场中的良好潜力，优先推动其在国内的销售推广工作，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600024383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","000661","BK0046","BK0239","BK0075","BK0057"],"gpt_icon":0},{"id":"2594826291","title":"长春高新(000661.SZ)：金赛药业GenSci141软膏注册临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594826291","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594826291?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:04","pubTimestamp":1766736287,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司子公司——长春金赛药业有限责任公司(以下简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GenSci141软膏注册临床试验申请获得受理。据悉，GenSci141软膏是金赛药业研发的一款双氢睾酮软膏,主要以旁分泌的方式在靶组织内发挥作用，属于化学药品2.2和2.4类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：金赛药业GenSci141软膏注册临床试验申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0075","000661","BK0188","BK0046","BK0057","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","002755","000661","02096","01801","02142","688428","LU2097828557.USD","LU2097828631.EUR","LU2580892862.HKD","LU1969619763.USD","09995","03692","LU0502904849.HKD","BK1589","BK0057","LU1328615791.USD","LU1064131003.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","BK0028","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","BK1161","603087","LU2148510915.USD","BK0188","02509","BK0060","688062","BK1593","688336","LU2495084118.USD","688331","01530","LU1997245094.SGD","LU2097828714.EUR","600276","LU1781817850.SGD","LU1146622755.USD","06978","BK1574","LU2097828805.USD","BK0012","BK0239","BK0196","01167"],"gpt_icon":0},{"id":"2593747051","title":"长春高新（000661）披露子公司GenSci145片临床试验申请获受理，12月24日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593747051","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593747051?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:10","pubTimestamp":1766585411,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，长春高新报收于94.09元，较前一交易日上涨0.43%，最新总市值为383.83亿元。该股当日开盘93.59元，最高94.17元，最低93.2元，成交额达3.6亿元，换手率为0.96%。公司近日发布公告称，子公司金赛药业提交的GenSci145片境内生产药品注册临床试验申请已获国家药品监督管理局受理。该药品适应症为携带PIK3CA突变的局部晚期或转移性实体瘤。GenSci145片为新型突变选择性PI3Kα抑制剂，临床前研究显示其具有较强的选择性抑制活性、有效性及良好的安全性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400040246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0057","BK0188","91272","BK0239","BK0028","BK0075"],"gpt_icon":0},{"id":"2593493159","title":"长春高新：无法掌握具体适应症占比的准确信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2593493159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593493159?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:54","pubTimestamp":1766480094,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月23日在投资者关系平台上答复投资者关心的问题。导致其他适应症同价，能否告知其他适应症占比多少？公司有无掌握其他在研在售产品，目前竞争对手上市阶段，有无研判竞品上市后销售策略？针对竞品公司的竞争，公司管理层有无考虑放弃那些多适应症性价比不高的研发投入！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300026240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","91272","BK0188","BK0075","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"1163188160","title":"长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1163188160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163188160?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:49","pubTimestamp":1765802949,"startTime":"0","endTime":"0","summary":"长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0057","000661","BK0075","BK0046","BK0028"],"gpt_icon":0},{"id":"1141150875","title":"长春高新宣布子公司与Yarrow Bioscience签署Gensci098注射剂项目许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1141150875","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141150875?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:47","pubTimestamp":1765802835,"startTime":"0","endTime":"0","summary":"长春高新宣布其子公司已与Yarrow Bioscience签署了涉及Gensci098注射剂项目的许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0057","000661","BK0075","BK0046","BK0028","BK0239"],"gpt_icon":0},{"id":"2591646738","title":"长春高新最新公告：下属公司签署GenSci098注射液项目独家许可协议可至多获得13.65亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646738","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591646738?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:39","pubTimestamp":1765802387,"startTime":"0","endTime":"0","summary":"长春高新公告称，下属公司上海赛增医疗科技有限公司与Yarrow Bioscience, Inc. 签订GenSci098注射液项目独家许可协议。根据协议，赛增医疗预计可获得1.2亿美元首付款及近期开发里程碑款项，并将有资格获得与特定研发、监管及商业化有关的里程碑付款。赛增医疗将有权就本次独家许可至多获得13.65亿美元里程碑付款，后续产品上市后并有权获得超过净销售额10%的销售提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500031815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","91272","BK0188","BK0075","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2591614862","title":"长春高新：长效生长激素规格及医保价格说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614862?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789570,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：金培生长激素上市了哪几个剂量规格，这次医保谈判落地价格分别是多少？公司现在说一下这个不违规吧，我们投资人想了解。长春高新回复：您好，公司长效产品主要有54IU/9.0mg/1.0ml/瓶、27IU/4.5mg/0.5ml/瓶两个规格，2026年1月1日最新版医保目录正式执行后相关价格可正式查询，具体请以国家相关部门披露为准，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","000661","BK0028","91272","BK0057","BK0075","BK0239","BK0188"],"gpt_icon":0},{"id":"2591261106","title":"长春高新：系统性推进市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261106?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:00","pubTimestamp":1765789253,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月15日在投资者关系平台上答复投资者关心的问题。请问公司是否会重新评估回购用途，考虑将部分股份用于注销以提升每股价值？公司2026年是否有明确市值管理、费用控制及提升分红或注销式回购？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0188","BK0075","91272","BK0239","BK0057","000661"],"gpt_icon":0},{"id":"2589337793","title":"长春高新(000661.SZ)子公司两款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589337793?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:54","pubTimestamp":1765184075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，据国家医疗保障局及人力资源社会保障部发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)自主研发的金赛增(现通用名为“金培生长激素注射液”)、合作引进的美适亚(通用名为“醋酸甲地孕酮口服混悬液”)均被新纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0075","BK0239","BK0188","BK0057","BK0046","91272","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768234609225,"stockEarnings":[{"period":"1week","weight":0.0578},{"period":"1month","weight":0.0257},{"period":"3month","weight":-0.2817},{"period":"6month","weight":-0.0402},{"period":"1year","weight":0.0698},{"period":"ytd","weight":0.0578}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":"　　长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}